PHOENIX — A new pancreatic cancer drug being tested by doctors in Phoenix is showing promise, potentially doubling survival rates for patients compared to chemotherapy alone.
Pancreatic cancer is one of the deadliest forms of the disease, according to the Centers for Disease Control and Prevention. Only one out of eight people lives for longer than five years, according to the American Cancer Society. Studies show patients with the diagnosis are often given three to 12 months to live, depending on their treatment.
However, according to new research presented by Revolution Medicine, a drug called daraxonrasib is giving doctors and patients a new reason for optimism. Dr. Erkut Borazanci is involved in active clinical trials using the drug at the HonorHealth Research Institute in Phoenix…